Population Pharmacokinetics of Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma and Exposure-Response in CLL

被引：71

作者：

Gibiansky, E. ^{[1
]}

Gibiansky, L. ^{[1
]}

Carlile, Dj ^{[2
]}

Jamois, C. ^{[3
]}

Buchheit, V. ^{[3
]}

Frey, N. ^{[3
]}

机构：

[1] QuantPharm LLC, North Potomac, MD 28078 USA

[2] Roche Prod Ltd, Welwyn Garden City, Herts, England

[3] F Hoffmann Roche Ltd, Basel, Switzerland

来源：

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY | 2014年 / 3卷 / 10期

关键词：

D O I：

10.1038/psp.2014.42

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Treatment regimens involving obinutuzumab (GA101) demonstrated increased efficacy to rituximab in clinical trials for non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL). However, the pharmacokinetic (PK) properties and the exposure-response relationships of obinutuzumab still need to be fully described. Data from four clinical trials of obinutuzumab were analyzed to describe the PK properties in patients with NHL or CLL and the pharmacodynamic (PD) properties in patients with CLL. A population PK model with linear time-dependent clearance described the obinutuzumab concentration-time course. Diagnosis, baseline tumor size (BSIZ), body weight, and gender were the main covariates affecting obinutuzumab exposure. In patients with CLL, exposure was not associated with safety but showed positive trends of correlation with efficacy. Although efficacy correlated positively with exposure, since both efficacy and exposure correlated negatively with BSIZ, it was not possible to determine with certainty whether it would be beneficial to adjust the dose according to BSIZ.

引用

页数：11

共 46 条

[1]

Australian Government Department of Health and Ageing, 2011, AUSTR PUBL ASS REP R

[2]

Beal S, 2011, NONMEM USERS GUIDES

[3] Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models [J].

Bergstrand, Martin ;

Hooker, Andrew C. ;

Wallin, Johan E. ;

Karlsson, Mats O. .

AAPS JOURNAL, 2011, 13 (02) :143-151

[4] Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia [J].

Cheson, BD ;

Bennett, JM ;

Kopecky, KJ ;

Büchner, T ;

Willman, CL ;

Estey, EH ;

Schiffer, CA ;

Döhner, H ;

Tallman, MS ;

Lister, TA ;

LoCocco, F ;

Willemze, R ;

Biondi, A ;

Hiddemann, W ;

Larson, RA ;

Löwenberg, B ;

Sanz, MA ;

Head, DR ;

Ohno, R ;

Bloomfield, CD .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (24) :4642-4649

[5] CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. [J].

Coiffier, B ;

Lepage, E ;

Brière, J ;

Herbrecht, R ;

Tilly, H ;

Bouabdallah, R ;

Morel, P ;

Van den Neste, E ;

Salles, G ;

Gaulard, P ;

Reyes, F ;

Gisselbrecht, C .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (04) :235-242

[6] Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte [J].

Coiffier, Bertrand ;

Thieblemont, Catherine ;

Van Den Neste, Eric ;

Lepeu, Gerard ;

Plantier, Isabelle ;

Castaigne, Sylvie ;

Lefort, Sophie ;

Marit, Gerald ;

Macro, Margaret ;

Sebban, Catherine ;

Belhadj, Karim ;

Bordessoule, Dominique ;

Ferme, Christophe ;

Tilly, Herve .

BLOOD, 2010, 116 (12) :2040-2045

[7] The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas:: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group [J].

Forstpointner, R ;

Dreyling, M ;

Repp, R ;

Hermann, S ;

Hänel, A ;

Metzner, B ;

Pott, C ;

Hartmann, F ;

Rothmann, F ;

Rohrberg, R ;

Böck, HP ;

Wandt, H ;

Unterhalt, M ;

Hiddemann, W .

BLOOD, 2004, 104 (10) :3064-3071

[8] Comparison of Nonmem 7.2 estimation methods and parallel processing efficiency on a target-mediated drug disposition model [J].

Gibiansky, Leonid ;

Gibiansky, Ekaterina ;

Bauer, Robert .

JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2012, 39 (01) :17-35

[9] Levels of expression of CD19 and CD20 in chronic B cell leukaemias [J].

Ginaldi, L ;

De Martinis, M ;

Matutes, E ;

Farahat, N ;

Morilla, R ;

Catovsky, D .

JOURNAL OF CLINICAL PATHOLOGY, 1998, 51 (05) :364-369

[10] Mechanisms of killing by anti-CD20 monoclonal antibodies [J].

Glennie, Martin J. ;

French, Ruth R. ;

Cragg, Mark S. ;

Taylor, Ronald P. .

MOLECULAR IMMUNOLOGY, 2007, 44 (16) :3823-3837

← 1 2 3 4 5 →